CL2024002643A1 - Formas puras de aticaprant cristalino - Google Patents
Formas puras de aticaprant cristalinoInfo
- Publication number
- CL2024002643A1 CL2024002643A1 CL2024002643A CL2024002643A CL2024002643A1 CL 2024002643 A1 CL2024002643 A1 CL 2024002643A1 CL 2024002643 A CL2024002643 A CL 2024002643A CL 2024002643 A CL2024002643 A CL 2024002643A CL 2024002643 A1 CL2024002643 A1 CL 2024002643A1
- Authority
- CL
- Chile
- Prior art keywords
- aticaprant
- crystalline
- pure forms
- solvates
- pure
- Prior art date
Links
- ZHPMYDSXGRRERG-DEOSSOPVSA-N aticaprant Chemical compound CC1=CC(C)=CC([C@H]2N(CCC2)CC=2C=CC(OC=3C(=CC(=CC=3)C(N)=O)F)=CC=2)=C1 ZHPMYDSXGRRERG-DEOSSOPVSA-N 0.000 title abstract 4
- 229940121408 aticaprant Drugs 0.000 title abstract 4
- 208000024714 major depressive disease Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263317483P | 2022-03-07 | 2022-03-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2024002643A1 true CL2024002643A1 (es) | 2025-01-24 |
Family
ID=85979414
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2024002643A CL2024002643A1 (es) | 2022-03-07 | 2024-09-03 | Formas puras de aticaprant cristalino |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20230348377A1 (enExample) |
| EP (1) | EP4489748A1 (enExample) |
| JP (1) | JP2025508071A (enExample) |
| KR (1) | KR20240158951A (enExample) |
| CN (1) | CN119156210A (enExample) |
| AU (1) | AU2023231493A1 (enExample) |
| CA (1) | CA3254503A1 (enExample) |
| CL (1) | CL2024002643A1 (enExample) |
| CO (1) | CO2024012457A2 (enExample) |
| IL (1) | IL315411A (enExample) |
| JO (1) | JOP20240195A1 (enExample) |
| MX (1) | MX2024010978A (enExample) |
| PE (1) | PE20242109A1 (enExample) |
| TW (1) | TW202345795A (enExample) |
| WO (1) | WO2023170547A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12161622B2 (en) | 2021-05-04 | 2024-12-10 | Janssen Pharmaceuticals, Inc. | Compositions and methods for the treatment of depression |
| CN119156211A (zh) | 2022-03-07 | 2024-12-17 | 杨森制药公司 | 用于治疗重性抑郁障碍的多晶型形式的阿替卡普兰 |
| EP4489730B1 (en) | 2022-03-07 | 2026-01-21 | Janssen Pharmaceuticals, Inc. | Compositions comprising aticaprant |
| CN117903050B (zh) * | 2024-03-15 | 2024-05-17 | 中国药科大学 | 阿立哌唑共晶及其药物组合物和应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009094260A1 (en) * | 2008-01-22 | 2009-07-30 | Eli Lilly And Company | Kappa selective opioid receptor antagonist |
| US10316021B2 (en) * | 2016-11-28 | 2019-06-11 | Pfizer Inc. | Heteroarylphenoxy benzamide kappa opioid ligands |
| AU2022268720A1 (en) * | 2021-05-04 | 2023-12-21 | Janssen Pharmaceuticals, Inc. | Compositions and methods for the treatment of depression |
-
2023
- 2023-03-06 WO PCT/IB2023/052082 patent/WO2023170547A1/en not_active Ceased
- 2023-03-06 US US18/179,025 patent/US20230348377A1/en not_active Abandoned
- 2023-03-06 JP JP2024553437A patent/JP2025508071A/ja active Pending
- 2023-03-06 CA CA3254503A patent/CA3254503A1/en active Pending
- 2023-03-06 AU AU2023231493A patent/AU2023231493A1/en active Pending
- 2023-03-06 CN CN202380038807.1A patent/CN119156210A/zh active Pending
- 2023-03-06 TW TW112108147A patent/TW202345795A/zh unknown
- 2023-03-06 PE PE2024001920A patent/PE20242109A1/es unknown
- 2023-03-06 KR KR1020247033036A patent/KR20240158951A/ko active Pending
- 2023-03-06 EP EP23715931.4A patent/EP4489748A1/en active Pending
- 2023-03-06 IL IL315411A patent/IL315411A/en unknown
-
2024
- 2024-09-03 CL CL2024002643A patent/CL2024002643A1/es unknown
- 2024-09-05 JO JOJO/P/2024/0195A patent/JOP20240195A1/ar unknown
- 2024-09-06 MX MX2024010978A patent/MX2024010978A/es unknown
- 2024-09-13 CO CONC2024/0012457A patent/CO2024012457A2/es unknown
-
2025
- 2025-06-30 US US19/254,965 patent/US20250326714A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN119156210A (zh) | 2024-12-17 |
| US20250326714A1 (en) | 2025-10-23 |
| JP2025508071A (ja) | 2025-03-21 |
| EP4489748A1 (en) | 2025-01-15 |
| JOP20240195A1 (ar) | 2024-09-05 |
| US20230348377A1 (en) | 2023-11-02 |
| IL315411A (en) | 2024-11-01 |
| CA3254503A1 (en) | 2023-09-14 |
| MX2024010978A (es) | 2024-12-06 |
| AU2023231493A1 (en) | 2024-10-24 |
| WO2023170547A1 (en) | 2023-09-14 |
| CO2024012457A2 (es) | 2024-09-30 |
| PE20242109A1 (es) | 2024-10-28 |
| KR20240158951A (ko) | 2024-11-05 |
| TW202345795A (zh) | 2023-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2024012457A2 (es) | Formas puras de aticaprant cristalino | |
| CO2023008362A2 (es) | Degradadores de irak y sus usos | |
| MX2021006154A (es) | Degradadores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos. | |
| CO2022008406A2 (es) | Degradadores de irak y usos de los mismos | |
| CO2021013339A2 (es) | Degradadores de stat y usos de los mismos | |
| CL2021003191A1 (es) | Inhibidores de tead y usos de los mismos | |
| CL2021003190A1 (es) | Inhibidores de tead y usos de los mismos | |
| CO2023014770A2 (es) | Degradadores de cdk2 y sus usos | |
| MX2023006719A (es) | Degradadores de cinasas asociadas con el receptor de interleucina 1 (irak) y sus usos. | |
| CO2021004141A2 (es) | Moduladores de la expresión de pnpla3 | |
| CO2022012594A2 (es) | Inhibidores del eif4e y sus usos | |
| CO2024004970A2 (es) | Agentes degradantes de tyk2 y sus usos | |
| NI202000085A (es) | Moduladores de la expresión de apol1 | |
| CO2022000214A2 (es) | Composiciones para el tratamiento de la pérdida del cabello | |
| CL2021002318A1 (es) | Métodos de tratamiento de amiloidosis al | |
| CL2024003587A1 (es) | Inhibidores de mek y usos de estos | |
| MX2025006853A (es) | Degradadores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos | |
| CO2021014747A2 (es) | Métodos para el tratamiento de βeta-talasemia | |
| MX2023008634A (es) | Análogos de rapamicina y usos de estos. | |
| MX2022014254A (es) | Anticuerpos anti-hemojuvelina (hjv) para tratar mielofibrosis. | |
| CO2021007006A2 (es) | Moduladores de la expresión de irf5 | |
| CL2024002103A1 (es) | Métodos para tratar amiloidosis al | |
| MX2021013117A (es) | Composiciones y metodos para el tratamiento del cancer. | |
| UY38472A (es) | Moduladores de la expresión de foxp3 | |
| MA70825B1 (fr) | Traitement de douleur associée à la sensibilisation centrale |